Learn About Chronic Polyradiculoneuritis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
New Jersey Pediatric Neuroscience Institute
Nizar Souayah is a Neurologist in Hackensack, New Jersey. Dr. Souayah is rated as an Elite provider by MediFind in the treatment of Chronic Polyradiculoneuritis. His top areas of expertise are Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Myasthenia Gravis, and Chronic Polyradiculoneuritis. Dr. Souayah is currently accepting new patients.
Phoenix Rehabilitation And Health Services Inc
Marinos Dalakas is a Neurologist and a Neuromusculoskeletal Medicine provider in Cranberry Township, Pennsylvania. Dr. Dalakas is rated as an Elite provider by MediFind in the treatment of Chronic Polyradiculoneuritis. His top areas of expertise are Stiff Person Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Hyperekplexia, Chronic Polyradiculoneuritis, and Laminectomy.
Eduardo Orazio-Nobile practices in Milan, Italy. Mr. Orazio-Nobile is rated as an Elite expert by MediFind in the treatment of Chronic Polyradiculoneuritis. His top areas of expertise are Chronic Demyelinizing Neuropathy with IgM Monoclonal, Chronic Polyradiculoneuritis, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
Summary: This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300...
Summary: The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.